Please use this identifier to cite or link to this item:
|Title:||Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission||Authors:||BUYSE, Marc
Lucchesi, Kathryn J.
Brune, Mats L.
Rowe, Jacob M.
|Issue Date:||2011||Publisher:||FERRATA STORTI FOUNDATION||Source:||HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 96 (8). p. 1106-1112||Abstract:||Background In trials designed to evaluate new therapies for hematologic malignancies, end points such as leukemia-free survival are often used as surrogates for overall survival in acute leukemia. We aimed to assess whether leukemia-free survival is an acceptable statistical surrogate for overall survival when applied to remission maintenance therapy for acute myeloid leukemia. Design and Methods Data were analyzed from a randomized Phase III trial of remission maintenance immunotherapy with histamine dihydrochloride plus low-dose interleukin-2 versus no treatment in adults with acute myeloid leukemia. A two-stage surrogate validation model was applied in which correlations between Kaplan-Meier estimates of leukemia-free survival and overall survival, and between log hazard ratios reflecting treatment effects were analyzed. Country of patient enrollment was the unit of analysis. Results Kaplan-Meier estimates of overall survival at 36, 48, and 60 months and leukemia-free survival at 24 months were reasonably correlated (R(2) ranging from 0.44 to 0.84) both for the overall (n=320) and first complete remission (n=261) populations. The effects of histamine dihydrochloride/interleukin-2 on log hazard ratios for leukemia-free survival and overall survival were well correlated (R(2)=0.88-0.93). Conclusions The significant correlations between overall survival and the surrogate end point (leukemia-free survival) and between the effect of histamine dihydrochloride/interleukin-2 on leukemia-free survival and overall survival satisfy the two-stage surrogate validation model. (ClinicalTrials.gov Identifier: NCT00003991)||Notes:||[Buyse, M; Squifflet, P] IDDI, B-1340 Louvain, Belgium [Buyse, M] Hasselt Univ, Ctr Stat, I BioStat, Diepenbeek, Belgium [Michiels, S] Inst Jules Bordet, B-1000 Brussels, Belgium [Lucchesi, KJ] MedVal Sci Informat Serv LLC, Skillman, NJ USA [Hellstrand, K; Brune, ML] Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden [Castaigne, S] Hop Andre Mignot, Le Chesnay, France [Rowe, JM] Rambam Med Ctr, Haifa, Israel [Rowe, JM] Technion Israel Inst Technol, Haifa, Israel email@example.com||Keywords:||leukemia-free survival; overall survival; immunotherapy; statistical analyses; clinical trial interpretation;leukemia-free survival; overall survival; immunotherapy; statistical analyses; clinical trial interpretation||Document URI:||http://hdl.handle.net/1942/12233||ISSN:||0390-6078||e-ISSN:||****-****||DOI:||10.3324/haematol.2010.039131||ISI #:||000294722700007||Category:||A1||Type:||Journal Contribution||Validations:||ecoom 2012|
|Appears in Collections:||Research publications|
Show full item record
Files in This Item:
|buyse 1.pdf||published version||405.73 kB||Adobe PDF||View/Open|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.